Literature DB >> 19919880

PACAP and VIP affect NF1 expression in rat malignant peripheral nerve sheath tumor (MPNST) cells.

Salvatore Giunta1, Alessandro Castorina, Alexander Adorno, Venera Mazzone, Maria Luisa Carnazza, Velia D'Agata.   

Abstract

In our previous study we have identified PACAP, VIP and their receptors in rat malignant peripheral nerve sheath tumor (MPNST) cells, thus showing anti-apoptotic roles. Recently it has been shown that the tumor suppressor neurofibromin, encoded by the Neurofibromatosis type I (NF1) gene, promotes MPNST cells sensitivity to apoptosis after serum withdrawal. In the present study we investigated whether PACAP or VIP negatively regulate NF1 expression under normal or serum-dependent pro-apoptotic culture conditions. Results indicated that serum itself significantly influenced gene and protein levels. In fact, the low NF1 levels of cells cultured in normal serum-containing medium were remarkably increased in cells switched to low- or no-serum after 24h and 48 h. Treatment with 100 nM PACAP or VIP did not affect NF1 expression when using normal amounts of serum, whereas it significantly inhibited transcript and protein levels both in low- or no-serum cultured cells. In particular, PACAP reduced NF1 levels already after 24h in low-serum cultured cells, while VIP showed a similar effect only after serum deprivation. However, both PACAP and VIP downregulated gene and protein levels within 48 h either in low-dose and serum-starved cells. Results were confirmed by fluorescence microscopy, showing that 100 nM PACAP or VIP attenuated neurofibromin cytoplasmic localization only in low- or no-serum cultured cells. The present study provides a comprehensive analysis of both neuropeptides effect on NF1 expression in normal, low- or serum-starved MPNST cells, ameliorating the hypothesis that resistance to apoptosis in serum-deprived cells might be correlated to PACAP-/VIP-induced NF1 inhibition. (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19919880     DOI: 10.1016/j.npep.2009.10.003

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  9 in total

1.  PACAP and VIP Mitigate Rotenone-Induced Inflammation in BV-2 Microglial Cells.

Authors:  Sarah Thomas Broome; Giuseppe Musumeci; Alessandro Castorina
Journal:  J Mol Neurosci       Date:  2022-02-24       Impact factor: 3.444

2.  Robust Dopaminergic Differentiation and Enhanced LPS-Induced Neuroinflammatory Response in Serum-Deprived Human SH-SY5Y Cells: Implication for Parkinson's Disease.

Authors:  Aram Niaz; Jocelyn Karunia; Mawj Mandwie; Kevin A Keay; Giuseppe Musumeci; Ghaith Al-Badri; Alessandro Castorina
Journal:  J Mol Neurosci       Date:  2020-08-13       Impact factor: 3.444

Review 3.  PACAP and NAP: Effect of Two Functionally Related Peptides in Diabetic Retinopathy.

Authors:  Agata Grazia D'Amico; Grazia Maugeri; Giuseppe Musumeci; Dora Reglodi; Velia D'Agata
Journal:  J Mol Neurosci       Date:  2021-01-05       Impact factor: 3.444

Review 4.  Emerging Role of PACAP as a New Potential Therapeutic Target in Major Diabetes Complications.

Authors:  Rubina Marzagalli; Soraya Scuderi; Filippo Drago; James A Waschek; Alessandro Castorina
Journal:  Int J Endocrinol       Date:  2015-05-14       Impact factor: 3.257

5.  PACAP interacts with PAC1 receptors to induce tissue plasminogen activator (tPA) expression and activity in schwann cell-like cultures.

Authors:  Alessandro Castorina; James A Waschek; Rubina Marzagalli; Venera Cardile; Filippo Drago
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

6.  PACAP and VIP Inhibit the Invasiveness of Glioblastoma Cells Exposed to Hypoxia through the Regulation of HIFs and EGFR Expression.

Authors:  Grazia Maugeri; Agata Grazia D'Amico; Rita Reitano; Gaetano Magro; Sebastiano Cavallaro; Salvatore Salomone; Velia D'Agata
Journal:  Front Pharmacol       Date:  2016-05-31       Impact factor: 5.810

7.  Pituitary adenylate cyclase-activating polypeptide attenuates tumor necrosis factor-α-induced apoptosis in endothelial colony-forming cells.

Authors:  Ning Bian; Gang Du; Man Fai Ip; Juan Ding; Qing Chang; Zicheng Li
Journal:  Biomed Rep       Date:  2017-05-23

Review 8.  Pituitary Adenylate Cyclase-Activating Polypeptide: 30 Years in Research Spotlight and 600 Million Years in Service.

Authors:  Viktoria Denes; Peter Geck; Adrienn Mester; Robert Gabriel
Journal:  J Clin Med       Date:  2019-09-18       Impact factor: 4.241

9.  Assessing the Anti-Inflammatory Activity of the Anxiolytic Drug Buspirone Using CRISPR-Cas9 Gene Editing in LPS-Stimulated BV-2 Microglial Cells.

Authors:  Sarah Thomas Broome; Teagan Fisher; Alen Faiz; Kevin A Keay; Giuseppe Musumeci; Ghaith Al-Badri; Alessandro Castorina
Journal:  Cells       Date:  2021-05-25       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.